Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 08:00 save search
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
skyrizi disease lancet risankizumab results phase 3
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Ulcerative Colitis
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
rinvoq lancet results phase 3 ulcerative colitis
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Published: 2022-05-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.29%
H: 1.3%
C: 0.74%
year one phase 3 ulcerative colitis
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial results growth hormone phase 3 topline
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | $18.41 -0.61% -0.61% 220K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3 elascestrant
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: -1.06%
H: 0.0%
C: 0.0%
zepzelca treatment trial lung cancer cancer phase 3
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818
Published: 2021-08-31 (Crawled : 08:00) - prnewswire.com
IGMS | $7.2 -2.83% -2.92% 220K
|
Health Technology
|
| O: 0.37%
H: 1.35%
C: -2.63%
phase 1 approval phase 2 phase 3
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -3.51%
europe phase 3
Progress Report for Phase 1 and Phase 2 of Nouveau Monde’s Bécancour Battery Anode Material Plants
Published: 2021-06-08 (Crawled : 08:00) - globenewswire.com
NMG | $2.03 -0.98% 0.25% 91K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.11%
H: 1.01%
C: -1.6%
OLN | $53.59 0.79% 0.0% 690K
|
Process Industries
|
| O: 0.0%
H: 2.94%
C: 1.95%
phase 2 battery phase 1 phase 3
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
Published: 2021-04-29 (Crawled : 08:00) - biospace.com/
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 1.58%
H: 0.44%
C: -2.55%
covid treatment phase 3 trial at-527
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.